Sanofi offers refunds for Cablivi in novel model for rebates
Pharmaceutical Technology
JANUARY 27, 2023
In 2019, Cablivi became the first FDA-approved , nanobody-based medicine for acquired thrombotic thrombocytopenic purpura (aTTP), an ultra-orphan condition that causes blood clots in small blood vessels around the body. The disorder has a reported annual incidence between 1.5 cases per million in Europe.
130 
Let's personalize your content